New approaches in the treatment of myelofibrosis

Cancer

Volumn 103, Issue 1, 2005, Pages 32-43

  Hennessy, Bryan T ^a   Thomas, Deborah A ^a   Giles, Francis J ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Idiopathic myelofibrosis; Myeloid metaplasia; Thalidomide; Treatment

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANAGRELIDE; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 8; CALMODULIN; CYCLOPHOSPHAMIDE; ETANERCEPT; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOMODULATORY IMIDE; LENALIDOMIDE; PEGINTERFERON; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SELECTIVE CYTOKINE INHIBITORY DRUG; SEMAXANIB; SURAMIN; THALIDOMIDE; THROMBOPOIETIN; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; BASOPHILIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; EDEMA; EXTRAMEDULLARY HEMATOPOIESIS; FATIGUE; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; MUSCULOSKELETAL DISEASE; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TUMOR VASCULARIZATION;

CLINICAL TRIALS; HUMANS; MYELOFIBROSIS; MYELOID METAPLASIA; PALLIATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 10844257532     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20752     Document Type: Review

References (121)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-1265.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999;17:2954-2970.
3. Reeder TL, Bailey RJ, Dewald GW, Tefferi A. Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. Blood. 2003;101:1981-1983.
4. Barosi G, Viarengo V, Rosti G, et al. Diagnostic and clinical relevance of the number of circulating CD34 positive cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249-3255.
5. Thiele J, Zankovich R, Steinberg T, et al. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis. A critical evaluation of clinical and histomorphological data. Acta Haematol. 1989;81:192-202.
6. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
7. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol. 1997;97:635-640.
8. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin Haematol. 1998;11:751-767.
9. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013-1018.
10. Mesa RA, Tefferi A. Survival and outcomes to therapy in leukemic transformation of myelofibrosis with myeloid metaplasia: a single institution experience with 91 patients [abstract]. Blood. 2003;102:917a-918a.
11. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374-3380.
12. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 1997;97:441-448.
13. Le Bousse-Kerdiles MC, Martyre MC. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. French INSERM Research Network on Idiopathic Myelofibrosis. Pathol Biol (Paris). 2001;49:153-157.
14. Komura E, Chagraoui H, Mansat de Mas V, et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp Hematol. 2003;31:622-630.
15. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88:9-16.
16. Martyre MC, Magdelenat H, Bryckaert MC, Laine-Bidron C, Calvo F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1991;77:80-86.
17. Raimundo FD, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15:976-980.
18. Wang JC, Hashmi G. Elevated thrombopoeitin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoeitin by bone marrow. Leuk Res. 2003;27:13-17.
19. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
20. low mice). Blood. 2002;100:1123-1132.
21. Rodriguez JN, Martino ML, Dieguez JC, et al. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica. 1998;83:616-621.
22. Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85:595-599.
23. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 1988;41:375-381.
24. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 1999;106:682-688.
25. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
26. Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: a review. Blood Rev. 1999;13:163-170.
27. Mesa RA, Tefferi A, Elliott MA, et al. A Phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridine), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:111-113.
28. Tefferi A, Silverstein MN, Plumhoff EA, Reid JM, Ames MM. Suramin toxicity and efficacy in agnogenic myeloid metaplasia. J Natl Cancer Inst. 1993;85:1520-1522.
29. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571. Erratum in: N Engl J Med. 2000;342:364.
30. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571. Erratum in: N Engl J Med. 2000;342:364.
31. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
32. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
33. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal mode of neovascularization. Exp Eye Res. 1997;64:971-978.
34. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
35. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
36. 1- acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production. Proc Natl Acad Sci U S A. 1996;93:7552-7556.
37. Thomas DA, Aguayo A, Giles FJ, et al. Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF) [abstract]. Blood. 1999;94:702a.
38. Pozzato G, Zorat F, Nascimben F, et al. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia. Haematologica. 2001;86:772-773.
39. Elliott MA, Geyer SM, Camoriano JK, et al. Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): an NCCTG study [abstract]. Blood. 2003;102:923a-924a.
40. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78-83.
41. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117:288-296.
42. Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol. 2001;115:313-315.
43. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16:1609-1614.
44. Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled analysis of individual patient data from 5 studies. Leuk Lymphoma. 2002;43:2301-2307.
45. Merup M, Kutti J, Birgergard G, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol. 2002;19:79-86.
46. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a Phase II trial. J Clin Oncol. 2004;22:424-431.
47. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol, 2004;72:52-57.
48. Mesa RA, Steensma DP, Pardanani A, et al. A Phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
49. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79:883-889.
50. Visani G, Mele A, Malagola M, et al. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents. Leukemia. 2003;17:1669-1670.
51. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production. Bioorg Med Chem Lett. 1999;9:1625-1630.
52. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999;558:107-113.
53. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer. 2002;87:1166-1172.
54. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
55. Barlogie B. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Semin Hematol. 2003;40(4 Suppl 4):33-38.
56. List AF, Kurtin S, Glinsmann-Gibson B, et al. Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS) [abstract]. Blood. 2003;102:184a.
57. Rebollo A, Martinez AC. Ras proteins: recent advances and new functions. Blood. 1999;94:2971-2980.
58. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
59. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-773.
60. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575-4580.
61. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
62. Mesa RA, Tefferi A, Gray LA, et al. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia. 2003;17:849-855.
63. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101:1692-1697.
64. Mesa RA, Camoriano JK, Geyer SM, et al. A Phase 2 Consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: interim analysis of 18 patients [abstract]. Blood. 2003;102:922a.
65. Body JJ. The syndrome of anorexia-cachexia. Curr Opin Oncol. 1999;11:255-260.
66. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92(6 Suppl):1684-1688.
67. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433-1450.
68. Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood. 1995;85:989-996.
69. Tsimberidou AM, Giles FJ. TNF-alpha targeted therapeutic-approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther. 2002;2:277-286.
70. Deaner P. Thalidomide for distressing night sweats in advanced malignant disease. Palliat Med. 1998;12:208-209.
71. Calder K, Bruera E. Thalidomide for night sweats in patients with advanced cancer. Palliat Med. 2000;14:77-78.
72. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002;99:2252-2254.
73. Tsimberidou AM, Thomas D, O'Brien S, et al. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002;50:237-242.
74. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
75. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
76. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
77. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440-2448.
78. Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A. 1995;92:2558-2562.
79. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (ST1571) therapy. Blood. 2004;103:3549-3551.
80. Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99:381-383.
81. Piaggio G, Castello S, Podestra M, et al. Low number of circulating CD34+ cells identifies a group of patients with myelofibrosis with myeloid metaplasia (MMM) who efficiently respond to STI571 [abstract]. Blood. 2001;98:628a.
82. Odenike O, Hoving K, Sher D, et al. Phase II study of imatinib mesylate (IM) in myelofibrosis with myeloid metaplasia (MMM) [abstract]. Proc Am Soc Clin Oncol. 2003;22:585.
83. Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003;97:2760-2766.
84. Ho AY, Lim S, Fishlock K, et al. Imatinib mesylate in myelofibrosis: preliminary results show early sustained improvements in platelet counts and splenomegaly [abstract]. Blood. 2002;100:799a.
85. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 study of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002;99:3854-3856.
86. Gisslinger H, Gisslinger B, Kees M, et al. Imatinib mesylate in chronic idiopathic myelofibrosis: a Phase II trial [abstract]. Blood. 2002;100:800a.
87. De Angelo DJ, Soiffer RJ, Galinisky I, et al. Imatinib mesylate (Gleevec) for patients with chronic idiopathic myelofibrosis (CIM): a Phase II trial [abstract]. Blood. 2003;102:146a.
88. Hasselbalch HC, Bjerrum OW, Jensen BA, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol. 2003;74:238-242.
89. Seifert RA, Coats SA, Raines EW, Ross R, Bowen-Pope DF. Platelet-derived growth factor (PDGF) receptor α-subunit mutant and reconstituted cell lines demonstrate that transforming growth factor-β can be mitogenic through PDGF A-chain-dependent and -independent pathways. J Biol Chem. 1994;269:13951-13955.
90. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
91. Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416 - a small molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer. 2003;97:1920-1928.
92. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000;60:4152-4160.
93. Hasselbalch HC. SU6668 in idiopathic myelofibrosis - a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. Med Hypotheses. 2003;61:244-247.
94. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK222484, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178-2189.
95. Giles FJ, List AF, Roboz GJ, et al. Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia [abstract]. Blood. 2003;102:922a.
96. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-α in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78:533-538.
97. Bukowski RM, Tendler C, Cutler D, et al. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer. 2002;95:389-396.
98. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a Phase III study. Leukemia. 2004;18:309-315.
99. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51:81-86.
100. Verstovsek S, Lawhorn K, Giles F, et al. PEG Intron therapy for patients with myeloproliferative diseases (MPD): interim analysis of Phase II study [abstract]. Blood. 2003;102:919a-920a.
101. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586-593.
102. McCarty J. Transplant strategies for idiopathic myelofibrosis. Semin Hematol. 2004;41:23-29.
103. Singhal S, Powles R, Treleaven J, et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant. 1995;16:743-746.
104. Anderson JE, Sale G, Appelbaum FR, et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol. 1997;98:1010-1016.
105. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol. 1997;98:1004-1009.
106. Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998;57:24-28.
107. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93:2831-2838.
108. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hemopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912-3918.
109. Daly A, Song K, Nevill T, et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant. 2003;32:35-40.
110. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004;33:1005-1009.
111. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood. 2002;99:2255-2258.
112. Hessling J, Kroger N, Werner M, et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;119:769-772.
113. Benesch M, Deeg HJ. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc. 2003;78:981-990.
114. Maziarz RT, Mesa RA, Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?" Mayo Clin Proc. 2003;78:941-943.
115. Platzbecken U, Ehninger G, Schmilz N, Bornhauser M. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases. Ann Hematol. 2003;82:463-468.
116. Rondelli D, Barosi G, Bacigalupo A, et al. Non-myeloablative allogeneic HSCT in high risk patients with myelofibrosis [abstract]. Blood. 2003;102:199a.
117. Ingram WA, Ho AY, Kenyon M, et al. Alemtuzumab containing reduced intensity conditioning regimen is safe and effective in myelofibrosis [abstract]. Blood. 2003;102:434b.
118. Tanvetyanon T, Stiff PJ, Toor AA, et al. Allogeneic stem cell transplantation (ASCT) for myelofibrosis [abstract]. Blood. 2003;102:472b.
119. Byrne JL, Beshti H, Clark D, et al. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. Br J Haematol. 2000;108:430-433.
120. Cervantes F, Rovira M, Urbano-Ispizua A, et al. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant. 2000;26:697-699.
121. Tefferi A, Deeg HJ. Deciding on transplantation for myelofibrosis: setting the record straight. Mayo Clin Proc. 2004;79:945-956.